交控科技公告，公司与Metro Trains West Pty Ltd签订合同金额为9353.04万澳大利亚元的项目协议。根据 该合同，公司将在项目交付阶段提供FAO系统，以支持全线列车全自动运行。 ...

2月9日，据西安银行披露，该行发行的金丝路聚利盈系列封闭式净值型理财产品（悦享分红款）202602 期募集期为2026年2月9日至2026年2月12日。个人投资者认购起始金额为1万元，机构投资者认购起始金 额为50万元。募集规模上限3亿元，下限1000万元。产品投资类型为固定收益类，内部风险评级为 （R2）中低风险，产品期限728天，业绩比较基准2.25%-3.05%（年化）。 （西安银行） 注：业绩比较基准不是预期收益率，不代表产品的未来表现和实际收益，不构成对产品收益的承诺。 以上理财产品信息仅供参考，具体应以《产品说明书》等销售文件为准。本文不构成任何投资建议，投 资者据此操作，风险自担。 ...

作者丨彭鑫 据小马智行消息，2月9日，首台量产版铂智4X Robotaxi正式下线，标志着小马智行与丰田中国、广汽 丰田的战略合作，正式迈入规模化生产与运营的全新阶段。铂智4X Robotaxi搭载了小马智行最新的第 七代自动驾驶乘用车系统。该系统融合了小马智行在北上广深等一线城市复杂环境中长期验证的技术能 力，并针对各类运营场景进行了系统级优化，实现了多项关键成果。小马智行与丰田中国、广汽丰田三 方的合资公司在2026年将部署千台级铂智4X Robotaxi，并在中国的一线城市开展运营。 编辑丨安安 ...

此前，多家科技巨头发布最新财报，制定了雄心勃勃的AI投资计划。这些科技巨头都是英伟达的忠实 客户。 分析指出，股东们对资本支出增加的反应不一，Meta和谷歌因广告和其他业务出现积极改善而受到投 资者青睐，微软和亚马逊则因AI相关业务增长不够快而受到冷遇。 #黄仁勋力挺科技巨头天量资本开支#【#黄仁勋力挺科技巨头超6000亿美元资本开支#：需求旺盛，AI 投资创造更多收入】近日，英伟达CEO黄仁勋在接受外媒采访时表示，科技行业在AI（人工智能）基 础设施方面不断增长的资本支出是合理、适当且可持续的，因为这些公司的现金流都将开始增长。他还 认为，AI基础设施建设仍处于早期阶段，未来几年内需求将持续旺盛。 黄仁勋表示："只要人们继续为AI付费，AI公司能够从中获利，那它们就会不断地翻倍、翻倍、翻倍、 再翻倍。" 其中，亚马逊预计，今年的资本支出将猛增五成至2000亿美元；谷歌母公司Alphabet预计，2026年支出 将在1750亿美元至1850亿美元之间；Meta表示，其资本支出可能比去年翻一番，达到1150亿美元至 1350亿美元之间；微软上财季资本支出同比增长创纪录的66%，高达375亿美元。 《华尔街日报》 ...

Core Insights - Novo Nordisk announced the official launch of injectable pegylated recombinant factor VIII (brand name: Nuwiq®) in mainland China, marking it as the only long-acting recombinant factor VIII approved in the country [1] - Nuwiq® has been added to the new national medical insurance catalog, enhancing accessibility for patients with Hemophilia A and ushering them into a new treatment phase [1] Group 1: Product and Market Impact - Nuwiq® fills a significant gap in long-term treatment for Hemophilia A in China, which affects approximately 80%-85% of all hemophilia patients [1] - The product's launch is expected to improve medication accessibility for patients, who require lifelong treatment to avoid severe health risks [1] Group 2: Clinical Data and Efficacy - Since its approval in the U.S. in 2019, Nuwiq® has accumulated extensive efficacy and safety data for the prevention and treatment of bleeding globally [1] - In a multi-center trial (Pathfinder10) conducted among Chinese Hemophilia A patients, the median annualized bleeding rate (ABR) for those receiving preventive treatment with Nuwiq® was 0.00, with 69.4% of patients experiencing zero bleeding events and a 94.8% success rate in stopping bleeding [1]

近日，据天眼查显示，自嗨锅关联公司杭州金羚羊企业管理咨询有限公司新增一则破产审查案件信息，案号为 （2026）浙0110破申18号，申请人为马某。 （天眼查） ...

Group 1: Company Performance and Strategy - Longping High-Tech's Brazilian operations have significantly improved, with measures taken to reduce losses despite challenges such as low global grain prices and high loan rates [1] - The company expects an increase in gross margin by over 8 percentage points year-on-year due to comprehensive cost control measures across supply chain, human resources, and taxation [1] - Financial expenses have decreased by over 90% year-on-year, aided by a RMB 4 billion syndicated loan that replaced high-interest debt, and effective management of foreign exchange risks [1] Group 2: Rice Business Outlook - The rice business maintains a market share of over 20% and focuses on high-quality operations, with plans to develop high-value varieties in response to market demand [2] - There is potential for growth in international markets, particularly in Southeast Asia, where the company can leverage its advantages in variety and technology [2] - The company aims to expand its specialized and innovative business segments, with steady growth in sunflower and chili seed businesses, while facing challenges in other segments due to market fluctuations [2] Group 3: Corn Business Challenges and Strategies - The corn seed industry is currently in a downturn due to supply-demand imbalances and price declines, with expectations of continued impact in the next couple of years [3] - The company is proactively preparing next-generation corn varieties and has maintained a relatively stable performance compared to peers [3] - The company plans to utilize its strong cash flow and reduced debt ratio to pursue external expansion opportunities, including acquisitions in the fresh corn sector [3]

Core Viewpoint - The company has announced a continuous related party transaction with Songhe Group, involving a procurement framework agreement for alcoholic beverages, which is deemed beneficial for the company's overall interests [1][6]. Group 1: Related Party Transactions - The board of directors has approved a procurement framework agreement between the company and Songhe Group for the supply of alcoholic beverages [1]. - As of the announcement date, Guoquan Industrial holds 33.52% of the company's issued share capital, making it one of the company's controlling shareholders [1]. - Songhe Group is an indirect subsidiary of Guoquan Industrial and is considered a related party to the company [1]. Group 2: Historical Transaction Amounts - The historical transaction amounts for purchasing alcoholic beverages from Songhe Group are as follows: 417,000 yuan in 2023, 31.59 million yuan in 2024, and 23.727 million yuan in 2025 [6]. - The annual cap for the supply of alcoholic beverages from Songhe Group to the company is set at 200 million yuan for the 11 months following the announcement until December 31, 2026 [6]. Group 3: Supplier Reliability and Benefits - Songhe Group is described as a stable and reliable supplier with expertise in white liquor brewing and customized product development [6]. - The quality and efficiency of the products provided by Songhe Group meet the company's requirements, and they can offer integrated supply services at reasonable costs [6]. - Compared to other suppliers, Songhe Group has a better understanding of the company's product positioning and store network needs, which is crucial for efficient supply chain integration [6].

Core Insights - The company reported a total operating revenue of 31.629 billion yuan for the year 2025, representing a year-on-year growth of 14.53% [1] - The net profit attributable to shareholders of the listed company reached 3.422 billion yuan, with a year-on-year increase of 1.60% [1] Strategic Focus - The company aims to adhere to a dual-driven strategy of "innovation + brand" to navigate a complex market environment [1] - The focus is on core treatment areas, expanding the research and development pipeline from multiple dimensions to uncover innovative value [1] - The company is committed to enhancing brand advantages, optimizing business layout, and forging a competitive edge across the entire industry chain to solidify its leading position in the industry [1] - The strategic goal is to strive to become a top enterprise in the industry [1]

新易盛在互动易回复称，公司表示生产经营情况正常，在手订单充足，结合当前客户需求指引及订单情 况，预计行业将持续保持高景气度。 ...